Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

38.10

+1.17 (3.17%)

as of Aug 25, 2026, 8:00:00 pm Market Open.

70 watching

Investor Insights

Aug 25, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

Teva Pharmaceutical, currently rated TEVA-N, has gained attention due to a recent credit rating upgrade from Moody's, emphasizing the success of its growth strategy bolstered by key innovative products, a robust pipeline, and ongoing debt reduction. Despite some fluctuations in stock performance and concerns regarding the pharmaceutical sector's competitiveness, especially with generics entering the market, Teva's operational metrics are improving, including revenue diversity and solid free cash flow. The leadership under the current CEO has been particularly transformative, seeing a significant turnaround since early 2023. However, experts highlight mixed sentiments about Teva's innovative capabilities, suggesting caution for investors looking for standout pharmaceuticals. Nonetheless, the stock has shown strong accumulation and resilience in a favorable drug market lately.

Consensus

Positive

Valuation

Fair Value

Similar

Pfizer,PFE

COMMENT

Very big in the generic market. First class company. 1.5% yield. Would prefer Johnson & Johnson (JNJ-N).

BUY

Largest generic pharmaceutical company globally. Having a lot of trouble getting around $50. Great company and is not expensive. Earnings will come in around $5, trading at 10X earnings. Has a terrific outlook.

BUY

Most of their drugs are generic. #1 drug is a blockbuster for MS but competition came out with a drug that had good results. Only trades at 10X earnings and has fast growth. Missed its last quarter giving an opportunity to buy at a 20% discount. With an 8 to 12 month time horizon you should do well.

DON'T BUY

Generic drugs. Has had great success over time taking drugs that are coming off patent and reformulating them. Have had a couple of hiccups in the last year or so in getting new drugs approved. Have a couple of non-generic drugs that are now being challenged by generics. Have missed a couple of estimates in a row. Prefers Perrigo (PRGO-Q).

TOP PICK

Forth quarter earnings and guidance were not what the analysts were looking for and the stock dropped. Thinks they will earn about $5/share in 2011. Significant free cash flow, double digit growth, best pipeline of any of the generic manufacturers. Very, very shareholder friendly. 25% discount to its piers.

COMMENT

Sold half his position when it was higher. Really 2 companies. Biggest part is generics. They are the biggest manufacturer globally. A lot of patented drugs will become invalid and they will grow because of it. They are also a pharmaceutical because they have a few drugs. One of them is an MS drug and a large part of their profits. It too is possibly coming up for generic competition, which has held the stock back but this is an opportunity. Probably won’t go any where for a little while. (See Top Picks.)

BUY

Loves the generic drug theme, which is a theme that will continue over the next couple of years as governments continue to cut health care coasts. Good growth.

BUY

Generic pharmaceutical company out of Israel and is the best in that market. Well run. If you have a long-term view, you should own this one.

COMMENT

Could be some major strengths in generic drugs going forward.

PAST TOP PICK

(A Top Pick Nov 26/09. Down 3.11%.) Still likes.

HOLD

Has owned for quite some time. Likes outlook for generic drug companies. They also have some of the their own drugs. There are competing drugs coming out and could be so-so for them. He sold half a couple of months ago. Likes health care in general: valuations are low and dividends are growing and there will be more demand for health-care in the US.

TOP PICK

World leader in generic drug manufacturing. Significant operations in Europe and the US. Made a couple of good acquisitions. Will benefit when other companies drugs come off patent.

BUY

One of the world's largest generic drug manufacturers. 25% global market share. Expect they can consistently grow earnings in the 10%-12% range. His target would be $55.

TOP PICK

Primarily a generic drug manufacturer. Market has overreacted with the challenge it is facing with from a competitor on one of its branded drugs. 1.5% yield.

BUY ON WEAKNESS

Leading generic drug manufacturer globally. Good growth profile. Valuations in the $40-$50 range would be decent. Growth rate is in the high mid-teens too low $20's.

Showing 166 to 180 of 277 entries

Most Recent Experts

Jason Del Vicario

HollisWealth

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Teva Pharmaceutical (TEVA)